Total (n = 177) | Female (n = 96) | Male (n = 81) | P-value | |
---|---|---|---|---|
# (%) | # (%) | # (%) | ||
BMI | 0.089 | |||
Severe underweight | 104 (59) | 49 (51) | 55 (68) | |
Moderate underweight | 22 (12) | 15 (16) | 7 (8.6) | |
Mild underweight | 18 (10) | 9 (9.4) | 9 (11) | |
Normal | 32 (18) | 22 (23) | 10 (12) | |
Normal (increased risk) | 1 (0.6) | 1 (1.0) | 0 (0.0) | |
CD4 count | 0.827 | |||
< 200 | 1 (0.6) | 1 (1.0) | 0 (0.0) | |
200–350 | 7 (4.0) | 4 (4.2) | 3 (3.7) | |
351–500 | 23 (13) | 14 (15) | 9 (11) | |
> = 500 | 146 (82) | 77 (80) | 69 (85) | |
Viral load (copies/mL) | 0.050 | |||
< 250 | 165 (93) | 89 (93) | 76 (94) | |
250–1000 | 3 (1.7) | 0 (0.0) | 3 (3.7) | |
> 1000 | 9 (5.1) | 7 (7.3) | 2 (2.5) | |
Tanner Stage | 0.007 | |||
1 | 63 (36) | 23 (24) | 40 (49) | |
2 | 41 (23) | 25 (26) | 16 (20) | |
3 | 32 (18) | 19 (20) | 13 (16) | |
4 | 23 (13) | 15 (16) | 8 (10) | |
5 | 18 (10) | 14 (15) | 4 (4.9) | |
PHQ9 Score | 1.000 | |||
Minimal depression | 176 (99) | 95 (99) | 81 (100) | |
Mild depression | 1 (0.6) | 1 (1.0) | 0 (0.0) | |
Moderate depression | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Co-morbidities and adverse effects | ||||
Lipodystrophy | 74 (42) | 40 (42) | 34 (42) | 0.967 |
Neuropathy | 7 (4.0) | 3 (3.1) | 4 (4.9) | 0.704 |
Renal Insufficiencya | 2 (1.1) | 2 (2.1) | 0 (0.0) | 0.344 |
Hypercholesterolemiab | 1 (0.6) | 0 (0.0) | 1 (1.2) | 0.208 |
Hypertriglyceridemiac | 32 (18) | 17 (18) | 15 (19) | 0.761 |
HBsAG | 3 (1.7) | 2 (2.1) | 1 (1.2) | 1.000 |
Hepatitis C antibodies | 1 (0.6) | 1 (1.0) | 0 (0.0) | 1.000 |
History of opportunistic infections | ||||
Pulmonary Tuberculosis | 97 (55) | 54 (56) | 43 (53) | 0.674 |
Extrapulmonary Tuberculosis | 21 (12) | 12 (13) | 9 (11) | 0.776 |
Oral esophageal candidiasis | 6 (3.4) | 5 (5.2) | 1 (1.2) | 0.221 |
Pneumocystis pneumonia | 1 (0.6) | 1 (1.04) | 0 (0.0) | 1.000 |
Disseminated non-TB mycobacteria | 1 (0.6) | 1 (1.04) | 0 (0.0) | 1.000 |